Key Points
- EVP Paul Mahon sold 8,300 shares at an average price of $565.87 for a total of $4,696,721, leaving him with 45,172 shares (a 15.52% reduction); the sale was disclosed in an SEC filing and executed under a Rule 10b5‑1 plan.
- CEO Martine Rothblatt and CFO James Edgemond also executed multi‑thousand‑share sales in late March/early April under pre‑arranged 10b5‑1 plans, a pattern that can be interpreted as near‑term profit‑taking despite being pre‑scheduled.
- Phase‑3 Tyvaso (IPF) results met the study's primary endpoint, driving bullish sentiment and prompting several analyst price‑target increases; MarketBeat shows a consensus rating of "Moderate Buy" with a $586 target.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the firm's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $565.87, for a total value of $4,696,721.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company's stock, valued at approximately $25,561,479.64. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
United Therapeutics Trading Down 1.0%
NASDAQ UTHR opened at $564.81 on Friday. The firm has a market capitalization of $24.76 billion, a PE ratio of 20.24, a price-to-earnings-growth ratio of 1.66 and a beta of 0.75. The business's 50-day moving average price is $504.78 and its two-hundred day moving average price is $477.55. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm's revenue was up 7.4% compared to the same quarter last year. During the same period last year, the company earned $6.19 earnings per share. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Institutional Trading of United Therapeutics
Large investors have recently modified their holdings of the stock. Torren Management LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on UTHR. HC Wainwright boosted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research report on Tuesday. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research report on Tuesday. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. Finally, Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $586.00.
Check Out Our Latest Report on UTHR
Key Headlines Impacting United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Phase‑3 Tyvaso (IPF) results met the study's key endpoint, a material clinical success that supports revenue upside and longer‑term product expansion for United Therapeutics. This is the primary bullish catalyst behind the recent run‑up. United Therapeutics Is Up After Positive Tyvaso Data
- Positive Sentiment: Multiple sell‑side analysts have reacted favorably: HC Wainwright keeps a Buy and $660 target while tweaking quarterly EPS estimates (raising Q3, trimming Q1/Q2 modestly), and other brokers issued bullish notes/upgrades — supporting a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
- Neutral Sentiment: Options activity is unusually high, suggesting traders are positioning around recent news and earnings risk; this can amplify intraday moves but is not a directional fundamental change. United Therapeutics Target of Unusually High Options Trading
- Neutral Sentiment: Coverage pieces and valuation analysis are appearing (assessments of Tyvaso's impact on valuation); these shape investor expectations but don't alter the underlying clinical win. Assessing United Therapeutics Valuation After Tyvaso Results
- Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond all sold multi‑thousand share blocks in late March/early April (sales executed under Rule 10b5‑1 plans). The size and timing of these sales (millions of dollars each) can be interpreted as near‑term negative pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
